2019
DOI: 10.3384/diss.diva-161677
|View full text |Cite
|
Sign up to set email alerts
|

Studies for Better Treatment of Patients with Glioma

Abstract: Previously published papers I and II and additional material included in this thesis have been reprinted with permission of the copyright holder. Paper III is included as Accepted Manuscript. This is a pre-copyedited, author-produced version of an article accepted for publication in Neuro-Oncology Practice following peer review. The version of record: Annika Malmström et al. Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma. Neuro-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 79 publications
0
2
0
Order By: Relevance
“…LGGs tend to affect younger patients more frequently, with a median age at diagnosis of 44 [7]. Numerous studies emphasize that a younger age is often associated with mutational status.…”
Section: Classification Performance Of Most Informative Features and ...mentioning
confidence: 99%
See 1 more Smart Citation
“…LGGs tend to affect younger patients more frequently, with a median age at diagnosis of 44 [7]. Numerous studies emphasize that a younger age is often associated with mutational status.…”
Section: Classification Performance Of Most Informative Features and ...mentioning
confidence: 99%
“…Some subsets of LGGs can evolve into GBM within a few months, whereas others may maintain stability for several years [6]. GBM is the most common and most aggressive type of glioma, accounting for more than 50% of all gliomas and is the most common malignant primary brain tumor [7][8][9]. GBM is a relatively uncommon tumor with a global incidence rate of only 3.17 per 100,000 people; however, GBM has a profound impact on patients' lives due to its grim prognosis, with a median survival of only 12-15 months from diagnosis [10,11].…”
Section: Introductionmentioning
confidence: 99%